| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 67,225 | 58,178 | 52,353 | 39,778 | 35,358 |
| Sales Growth | +15.55% | +11.13% | +31.61% | +12.50% | +21.03% |
| Net Income | -607 | 1,911 | 2,434 | 971 | 793 |
| Net Income Growth | -131.77% | -21.51% | +150.62% | +22.43% | -73.20% |
Hamilton Thorne Ltd (HTL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Hamilton Thorne Ltd is engaged in providing precision instruments, consumables, software, and services that reduce cost, increase productivity, improve results, and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. The company markets its products and services under the Hamilton Thorne, Gynemed, and Embryotech Laboratories brands, through its growing sales force and distributors. The company's customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments. It has a single reporting segment being Engaged in Sales to the ART, Research, and Cell Biology Markets.
Fiscal Year End Date: 12/31